Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Repertoire will receive $85 million upfront and up to $1.84 billion more for ?certain development and commercial milestones, as well as tiered royalties on net sales. The companies will aim to develop treatments that will restore the immune system and achieve durable remission of disease, without the ?generalized immune suppression common ?with current therapies. Lilly will also gain access to Repertoire's Decode platform that looks at how a type ?of white blood cell called T cells recognize and bind to specific targets on diseased cells, helping identify potential therapy candidates. Last month, Repertoire had ?said it is partnering with Pfizer to help develop potential ?T-cell–based therapies for advanced prostate cancer using the Decode platform. Under the terms of the agreement with Lilly, Repertoire will lead the collaboration until early discovery, and Lilly will lead clinical development, manufacturing, regulatory affairs and commercialization. Lilly has been activel
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer: A High-Yield Pharma At A Turning Point [Seeking Alpha]Seeking Alpha
- Pfizer (NYSE:PFE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Pfizer (NYSE:PFE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership [Yahoo! Finance]Yahoo! Finance
- Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 1/16/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- PFE's page on the SEC website